Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects
This study has been completed.
First Posted: May 23, 2005
Last Update Posted: April 26, 2013
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by (Responsible Party):
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||July 2005|
|Primary Completion Date:||July 2005 (Final data collection date for primary outcome measure)|
Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007 Jan;156(1):138-42.